Who Paid My Doc
PDE4 Phase III trial in PF-ILD
Research payments
$2,727,755
Through program year 2025, $2,727,755 in research payments was reported against PDE4 Phase III trial in PF-ILD, across 631 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $55,573 | 480 |
| 2024 | Research | $2,672,182 | 151 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Srihari Veeraraghavan Atlanta, GA Named on 33 payments
- Curtis Mello North Dartmouth, MA Named on 30 payments
- Yolanda Mageto Dallas, TX Named on 29 payments
- Oksana Shlobin Falls Church, VA Named on 28 payments
- Jeffrey Swigris Denver, CO Named on 27 payments
- Sean Levy Boston, MA Named on 26 payments
- Stephen Halliday Madison, WI Named on 25 payments
- Erin Blackstock Salt Lake City, UT Named on 22 payments
- Peter Lacamera Boston, MA Named on 21 payments
- Sachin Chaudhary Tucson, AZ Named on 20 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.